Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Assets: 2016-2024

Historic Other Non-Current Assets for Tg Therapeutics (TGTX) over the last 9 years, with Dec 2024 value amounting to $2.1 million.

  • Tg Therapeutics' Other Non-Current Assets fell 3.26% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 3.26%. This contributed to the annual value of $2.1 million for FY2024, which is 10.18% down from last year.
  • Per Tg Therapeutics' latest filing, its Other Non-Current Assets stood at $2.1 million for FY2024, which was down 10.18% from $2.3 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Other Non-Current Assets peaked at $2.3 million during FY2023, and registered a low of $1.3 million during FY2020.
  • In the last 3 years, Tg Therapeutics' Other Non-Current Assets had a median value of $2.1 million in 2024 and averaged $1.9 million.
  • In the last 5 years, Tg Therapeutics' Other Non-Current Assets skyrocketed by 81.38% in 2023 and then fell by 10.18% in 2024.
  • Tg Therapeutics' Other Non-Current Assets (Yearly) stood at $1.3 million in 2020, then increased by 0.40% to $1.3 million in 2021, then increased by 0.71% to $1.3 million in 2022, then spiked by 81.38% to $2.3 million in 2023, then fell by 10.18% to $2.1 million in 2024.